Name File Type Size Last Modified
  POL2015-0588_data 10/13/2019 05:23:AM
LICENSE.txt text/plain 14.6 KB 10/13/2019 01:23:AM

Project Citation: 

Dafny, Leemore, Ody, Christopher, and Schmitt, Matt. Replication data for: When Discounts Raise Costs: The Effect of Copay Coupons on Generic Utilization. Nashville, TN: American Economic Association [publisher], 2017. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2019-10-13. https://doi.org/10.3886/E114678V1

Project Description

Summary:  View help for Summary Branded pharmaceutical manufacturers frequently offer "copay coupons" that insulate consumers from cost-sharing, thereby undermining insurers' ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry between 2007 and 2010. To overcome endogeneity concerns, we exploit cross-state and cross-consumer variation in coupon legality. We find that coupons increase branded sales by 60+ percent, entirely by reducing the sales of bioequivalent generics. During the five years following generic entry, we estimate that coupons increase total spending by $30 to $120 million per drug, or $700 million to $2.7 billion for our sample alone.

Scope of Project

JEL Classification:  View help for JEL Classification
      G22 Insurance; Insurance Companies; Actuarial Studies
      I13 Health Insurance, Public and Private
      L11 Production, Pricing, and Market Structure; Size Distribution of Firms
      L65 Chemicals; Rubber; Drugs; Biotechnology; Plastics
      M31 Marketing


Related Publications

Published Versions

Export Metadata

Report a Problem

Found a serious problem with the data, such as disclosure risk or copyrighted content? Let us know.

This material is distributed exactly as it arrived from the data depositor. ICPSR has not checked or processed this material. Users should consult the investigator(s) if further information is desired.